Indian NGO wants Gilead patents cancelled
15-04-2020
Gilead told to waive remdesivir patent rights
02-04-2020
Gilead expands special access to potential COVID-19 drug
31-03-2020
Sundry Photography / Shutterstock.com
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, orphan drug, COVID-19, coronavirus, antiviral, remdesivir, FDA, Bernie Sanders, monopoly, pandemic
